Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

ARS Pharmaceuticals (SPRY) EBT (2022 - 2025)

Historic EBT for ARS Pharmaceuticals (SPRY) over the last 4 years, with Q3 2025 value amounting to -$53.2 million.

  • ARS Pharmaceuticals' EBT fell 14458.34% to -$53.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$90.8 million, marking a year-over-year decrease of 5004.46%. This contributed to the annual value of $8.3 million for FY2024, which is 11524.14% up from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' EBT is -$53.2 million, which was down 14458.34% from -$47.6 million recorded in Q2 2025.
  • Over the past 5 years, ARS Pharmaceuticals' EBT peaked at $47.2 million during Q4 2024, and registered a low of -$53.2 million during Q3 2025.
  • Moreover, its 4-year median value for EBT was -$15.4 million (2022), whereas its average is -$16.3 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' EBT plummeted by 22476.36% in 2023, and later soared by 56153.92% in 2024.
  • Quarter analysis of 4 years shows ARS Pharmaceuticals' EBT stood at -$15.4 million in 2022, then soared by 33.78% to -$10.2 million in 2023, then surged by 561.54% to $47.2 million in 2024, then plummeted by 212.7% to -$53.2 million in 2025.
  • Its last three reported values are -$53.2 million in Q3 2025, -$47.6 million for Q2 2025, and -$37.2 million during Q1 2025.